MDGL Madrigal Pharmaceuticals, Inc.
Healthcare$517.26+0.71%ClosedMarket Cap: $11.93B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
27.63
P/S
10.53
EV/EBITDA
-41.86
DCF Value
$2,832.51
FCF Yield
-2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.1%
Operating Margin
-27.7%
Net Margin
-27.3%
ROE
-50.2%
ROA
-25.2%
ROIC
-35.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $311.3M | 91.4% | $-92.7M | $-94.4M | $— | — |
| Q4 null | $321.1M | 92.4% | $-59.6M | $-58.6M | $— | — |
| FY null | $958.4M | 94.1% | $-300.1M | $-288.3M | $— | — |
| Q3 null | $287.3M | 93.7% | $-114.0M | $-114.2M | $— | — |
| Q2 null | $212.8M | 95.7% | $-47.2M | $-42.3M | $— | — |
| Q1 null | $137.3M | 96.7% | $-79.3M | $-73.2M | $— | — |
| Q4 null | $103.3M | 96.7% | $-67.0M | $-59.4M | $— | — |
| FY null | $180.1M | 96.5% | $-497.9M | $-465.9M | $— | — |
| Q3 null | $62.2M | 96.5% | $-116.3M | $-107.0M | $— | — |
| Q2 null | $14.6M | 95.7% | $-162.5M | $-152.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-152.0M | $-147.5M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-117.2M | $-112.2M | $-5.68 | — |